Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

World-class formula for fighting disease

28.01.2005


One of the most exciting developments in clinical research in decades is taking place at the University of Leeds, led by our professor of cancer medicine Peter Selby in collaboration with the Medical Research Council. The creation of a new network for world-class researchers in subjects such as medicines for children, Alzheimer’s, diabetes, mental health and strokes will benefit patients through translating cutting-edge research into new forms of treatment and the best possible chance of recovery.

In 2001, Professor Selby set up the National Cancer Research Network (NCRN). The network has already doubled the number of people involved in cancer clinical trials from 7,500 to 20,000 each year in England and is improving the quality and participation in clinical cancer research.

The model is now being extended across a wide range of diseases as the UK Clinical Research Network. The aim is to ensure that more patients benefit from leading edge medical research as quickly as possible and, following a competitive tender, Leeds is again to be at the forefront of the work. “The creation of the UK Clinical Research Network is the most exciting development in clinical research nationally – or indeed internationally – in recent decades,” Professor Selby said. “It will bring together partner organisations to speed up the development of new medicines and treatments from the laboratory to the patient’s bedside, meaning more patients benefit from the latest scientific advances and ensure health care is based on sound evidence. Our evidence-based approach should place the UK at the forefront of clinical research.”



In addition, the news means the University of Leeds can truly claim a world-class level of expertise, Professor Selby said, enabling it to recruit some 35 staff to begin the new work.

The new network will be co-ordinated by a consortium of the University of Leeds, Leeds Teaching Hospitals NHS trust, University College London and the Medical Research Council clinical trials unit in London. The co-ordinating centre will be co-located in Leeds and London and will be directed by Professor Selby and Professor Janet Darbyshire of the Medical Research Council clinical trials unit. The government is providing substantial funding. In the last budget the health secretary announced an extra £100m a year by 2008 for research and development in the priority areas, the biggest ever increase in research funding targeting these diseases.

Professor Selby said that recent scientific advances in cell and molecular biology, molecular genetics, immunology and pharmacology had radically improved our basic understanding of the mechanisms of disease – and demonstrated many potential new approaches to its prevention, diagnosis and treatment. But turning this basic science into patient benefit required more high quality clinical research, which must be carried out against the background of ever increasing regulation to ensure patient safety.

In the UK these scientific needs have been addressed by substantial new government investment and the creation of networks designed to ensure rapid progress in clinical research. For research has shown that cancer patients being treated in units where a large proportion are enlisted on clinical trials tend to do better than the average, partly because trials generally bring a better standard of care.
“However, it can be difficult and time-consuming to get patients admitted to trials and many clinicians lack the time or resources to handle the extra workload. But the cancer network has proved it is possible to support the clinical researchers making admission into trials swifter and so speeding up the whole research effort.

Professor Selby said his team achieved their success by liaising closely with 34 local cancer networks up and down the country. “We aimed to give guidance centrally while encouraging local ownership,” he said. “Although ring-fenced money is clearly vital, our success was really about motivating people to come on board.” Once patients and clinicians had agreed to take part in trials, network staff were able to take over many of the difficult steps like co-ordinating disparate funding bodies, organising peer reviews and gaining regulatory approval for trials, as well as supporting patients in trials. The enthusiasm and support of patients has been a wonderful element in the NCRN.

Professor Selby set up a specialist medical oncology service in Leeds in 1988 and, with support from the NHS and other agencies and it has expanded around Yorkshire to become one of the country’s largest and most successful regional oncology services and training programmes. He was also a leading member of the expert advisory group which proposed – and achieved – the reorganisation of cancer services in the UK.

“This is an exciting time for researchers who are seeking to take the major advances of the biology laboratories and develop them into successful medical care,” he said. “In about five years time I fully expect the clinical research network to be even more comprehensive, covering most if not all the main healthcare areas – that is our ultimate aim.

Vanessa Bridge | alfa
Further information:
http://www.leeds.ac.uk

More articles from Health and Medicine:

nachricht Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

How herpesviruses win the footrace against the immune system

26.05.2017 | Life Sciences

Water forms 'spine of hydration' around DNA, group finds

26.05.2017 | Life Sciences

First Juno science results supported by University of Leicester's Jupiter 'forecast'

26.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>